<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883844</url>
  </required_header>
  <id_info>
    <org_study_id>HBV09-03</org_study_id>
    <nct_id>NCT00883844</nct_id>
  </id_info>
  <brief_title>PEG-IFN in HBV Patients With Incomplete Response to NA</brief_title>
  <acronym>PADD</acronym>
  <official_title>Lowering Viral Load With Nucleos(t)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Liver Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foundation for Liver Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with a nucleoside analogue and subsequent viral decline has shown to partially&#xD;
      restore immune hyporesponsiveness in chronic hepatitis B patients. Recent pilot studies&#xD;
      investigating whether the effect of lowering viral load with nucleoside analogue therapy&#xD;
      prior to the initiation of peginterferon results in higher sustained off-treatment responses&#xD;
      showed contradictory findings.&#xD;
&#xD;
      The aim of this study is to investigate sustained off-treatment response to peginterferon&#xD;
      alfa-2b in chronic HBeAg-positive hepatitis B patients who are pretreated with nucleos(t)ide&#xD;
      analogues, thereby lowering viral load&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained response defined as HBeAg loss and HBV DNA level &lt; 200 IU/mL</measure>
    <time_frame>at week 72</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuation of any Nucleos(t)ide analogue treatment and add-on of peginterferon for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuation of Nucleos(t)ide analogue mono-therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleos(t)ide analogue treatment with a peginterferon add-on strategy</intervention_name>
    <description>peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleos(t)ide analogue treatment</intervention_name>
    <description>Treatment with one of the approved nucleos(t)ide analogues</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hepatitis B (HBsAg positive &gt; 6 months)&#xD;
&#xD;
          -  HBeAg positive, anti-HBe negative within one month prior to initiation of&#xD;
             peginterferon alfa-2b&#xD;
&#xD;
          -  HBV DNA &lt; 2000 IU/ml during nucleos(t)ide analogue treatment within one month prior to&#xD;
             initiation of peginterferon alfa-2b&#xD;
&#xD;
          -  Compensated liver disease&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any investigational drug within 30 days of entry to this protocol&#xD;
&#xD;
          -  Severe hepatitis activity as documented by ALT&gt;10 x ULN&#xD;
&#xD;
          -  History of decompensated cirrhosis (defined as jaundice in the presence of cirrhosis,&#xD;
             ascites, bleeding gastric or esophageal varices or encephalopathy)&#xD;
&#xD;
          -  Pre-existent neutropenia (neutrophils &lt;1,800/mm3) or thrombocytopenia (platelets&#xD;
             &lt;90,000/mm3)&#xD;
&#xD;
          -  Co-infection with hepatitis C virus, hepatitis D virus or human immunodeficiency virus&#xD;
             (HIV)&#xD;
&#xD;
          -  Other acquired or inherited causes of liver disease: alcoholic liver disease, obesity&#xD;
             induced liver disease, drug related liver disease, auto-immune hepatitis,&#xD;
             hemochromatosis, Wilson's disease or alpha-1 antitrypsin deficiency&#xD;
&#xD;
          -  Alpha fetoprotein &gt; 50 ng/ml&#xD;
&#xD;
          -  Hyper- or hypothyroidism (subjects requiring medication to maintain TSH levels in the&#xD;
             normal range are eligible if all other inclusion/exclusion criteria are met)&#xD;
&#xD;
          -  Immune suppressive treatment within the previous 6 months&#xD;
&#xD;
          -  Contra-indications for alfa-interferon therapy like suspected hypersensitivity to&#xD;
             interferon or Peginterferon or any known pre-existing medical condition that could&#xD;
             interfere with the patient's participation in and completion of the study.&#xD;
&#xD;
          -  Pregnancy, breast-feeding&#xD;
&#xD;
          -  Other significant medical illness that might interfere with this study: significant&#xD;
             pulmonary dysfunction in the previous 6 months, malignancy other than skin&#xD;
             basocellular carcinoma in previous 5 years, immunodeficiency syndromes (e.g. HIV&#xD;
             positivity, auto-immune diseases, organ transplants other than cornea and hair&#xD;
             transplant)&#xD;
&#xD;
          -  Any medical condition requiring, or likely to require chronic systemic administration&#xD;
             of steroids, during the course of the study&#xD;
&#xD;
          -  Substance abuse, such as alcohol (&gt;80 g/day), I.V. drugs and inhaled drugs in the past&#xD;
             2 years.&#xD;
&#xD;
          -  Any other condition which in the opinion of the investigator would make the patient&#xD;
             unsuitable for enrollment, or could interfere with the patient participating in and&#xD;
             completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry LA Janssen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC, University Medical Center Rotterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC, University Medical Center Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 17, 2009</study_first_submitted>
  <study_first_submitted_qc>April 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2009</study_first_posted>
  <last_update_submitted>April 18, 2013</last_update_submitted>
  <last_update_submitted_qc>April 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>sustained response</keyword>
  <keyword>peginterferon</keyword>
  <keyword>nucleos(t)ide analogues</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

